Literature Compilation

Previous Page


This section includes the currently available and published information from a literature search (conducted 12 June 2019).

General reviews

Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1: e000023.

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.

Molecular diagnosis reviews

Hsiao SJ, Zehir A, Sireci AN et al. Detection of tumor NTRK gene fusions to identify patients who may benefit from TRK inhibitor therapy. J Mol Diagn 2019. doi: 10.1016/j.jmoldx.2019.03.008. [Epub ahead of print]

Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Path 2019; S1525-1578. doi: 10.1136/jclinpath-2018-205679. [Epub ahead of print]

Solomon JP, Hechtman JF. Detection of NTRK Fusions: Merits and limitations of current diagnostic platforms. Cancer Res 2019 Jul 1;79(13):3163-3168. doi: 10.1158/0008-5472.CAN-19-0372.

Therapeutic reviews

Kheder ES, Hong DS. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res 2018; 24: 5807-5814.

Consensus and guidelines

Marchio O, Scaltriti M, Ladanyi M et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol  2019 Jul 3. pii: mdz204. doi: 10.1093/annonc/mdz204. [Epub ahead of print]

Last update: 24 June 2019